IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
Rein Therapeutics (NASDAQ: RNTX) has announced the dosing of its first patient in the RENEW Phase 2 trial of LTI-03, targeting idiopathic pulmonary fibrosis (IPF). The trial will evaluate the safety, tolerability, and efficacy of LTI-03, a novel Caveolin-1-related peptide treatment.
The study is designed as a multi-center, randomized, double-blind, placebo-controlled trial that aims to enroll 120 patients across 50 global sites. Participants must have been diagnosed with IPF within 5 years of screening. The trial's primary endpoint focuses on treatment-emergent adverse events through Week 24, while secondary endpoints measure efficacy through FVC, ppFVC, and HRCT metrics. Rein is collaborating with IQVIA for enrollment, and topline interim data is expected in H1 2026.
IQVIA (NYSE:IQV) has announced a strategic collaboration with SCRI Development Innovations, the contract research organization arm of Sarah Cannon Research Institute, to enhance global oncology trials. The partnership combines IQVIA's global reach and expertise in managing one-fifth of U.S. oncology trials with SCRI's community oncology experience and Accelero operational model.
The collaboration aims to streamline clinical trial processes, reduce operational barriers, speed up data delivery, and accelerate the development of new cancer therapies. SCRI's Accelero model facilitates faster trial activation, improved recruitment, and seamless integration of electronic health records with data capture systems for U.S. clinical trials.
IQVIA Holdings (NYSE: IQV) announced that Ron Bruehlman, Executive Vice President and CFO, will present at the Bank of America Annual Health Care Conference on May 13, 2025, at 5:20 p.m. ET. Investors can access the live audio webcast through IQVIA's Investor Relations website, with a replay available later that day.
IQVIA (NYSE:IQV) announced that two of its executives have received prestigious Healthcare Businesswomen's Association (HBA) awards. Marie E. Lamont, head of Real World Solutions, has been named a Luminary, while Dr. Joanne Hackett, vice president of Health System Services, has been recognized as a Rising Star.
Lamont was recognized for enhancing patient voice in research and advancing women in healthcare. Since joining through the Inteliquet acquisition in 2021, she has led 800 colleagues across the U.S., India, and Europe, significantly improving operational performance. Hackett was honored for her scientific leadership, establishing key UK healthcare institutions, and revolutionizing IQVIA's precision medicine and genomics strategy.
Both executives will be celebrated at HBA's Woman of the Year Annual celebration in Chicago on May 9, 2025.
IQVIA (NYSE:IQV) has been recognized as a 'front-runner generative AI leader' for the life sciences industry by Everest Group® in their report 'AI-deas to Action: Operationalizing Generative AI in Life Sciences.' IQVIA stands out as the only clinical research organization (CRO) to achieve the highest front-runner ranking among 15 evaluated companies.
The company's Healthcare-grade AI® solutions have demonstrated leadership in integrating generative AI capabilities across research and development stages, focusing on patient journey analysis, clinical trial design, product commercialization strategies, and market access insights. IQVIA AI Assistant, their interactive tool for healthcare and life sciences insight generation, recently received the PM360 Innovation Award in the AI Category.
IQVIA Holdings (NYSE:IQV) has scheduled its first-quarter 2025 financial results announcement for Tuesday, May 6, 2025, before market opening. The management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day.
The earnings release and financial information will be available on IQVIA's Investor Relations website. Interested parties must pre-register for the conference call through a provided link, after which they will receive confirmation details including a unique passcode and registrant ID. A webcast replay will be accessible approximately two hours after the event concludes.
Biopharma R&D showed significant progress in 2024, with funding reaching a 10-year high of $102 billion, excluding pandemic peaks - a substantial increase from $71 billion in 2023. Clinical trial starts stabilized at 5,318, comparable to pre-pandemic levels of 5,316 in 2019.
The year saw 65 novel active substances launched globally, including breakthrough treatments in schizophrenia, MASH, rare neurological diseases, and non-oncology hematology. While this represents a decline from 80 launches in 2023, it surpasses pre-pandemic figures.
Notable improvements include increased Phase III trial success rates, though Phase I and II success rates declined. Inter-trial intervals improved to 17 months from the 2022 pandemic peak of 32 months. Companies are implementing productivity enablers including decision frameworks, clinical technologies, and artificial intelligence solutions to address R&D complexity amid economic and geopolitical challenges.
IQVIA (NYSE:IQV) has been recognized as a leader in the IDC MarketScape's 2024 assessment for decentralized clinical trial (DCT) technologies and consulting services. The company's leadership position is attributed to its extensive network of over 200 DCT consultants, comprehensive DCT-enabling technologies, and expertise in regulatory strategy implementation.
IDC's first assessment of DCT technology solutions highlights IQVIA's strengths in:
- Deep clinical and DCT implementation strategy expertise across therapeutic areas
- Healthcare-grade AI implementation across the value chain
- Novel GenAI tools for enhanced patient experience
- Country-wise regulatory strategy expertise
Decentralized clinical trials, which gained momentum during COVID-19, utilize telemedicine and mobile technologies to conduct trial activities remotely. This approach enables patient monitoring through wearable devices and digital tools, reducing the need for in-person site visits.